Pharma Intelligence is part of the Business Intelligence Division of Informa PLC
This is operated by a business or businesses owned by Informa PLC and all copyright resides with them. Informa PLC's registered office is 5 Howick Place, London SW1P 1WG. Registered in England and Wales. Number 8860726.
48 Total results for product and free and sample content found
Trialtrove
By Laura Runkel 19 Jun 2017
Biosimilars for autoimmune drugs, including humira, remicade, etanercept, rituximab and others, have been in clinical development for several years.
Topic Biosimilars
Trialtrove
By Doro Shin 31 May 2017
One Size No Longer Fits All comes to you from In Vivo, part of the Informa Pharma Intelligence suite of tools. Leveraging a unique array of news, data, analysis, and consulting products and services.
Topic Personalized Medicine
Trialtrove
By Christine Blazynski PhD 30 May 2017
Company pipeline depictions are snapshots that illustrate, at that point in time, where a therapeutic candidate sits in terms of development stage for a specific therapy area or disease.
Trialtrove
By Ethan Hebert 19 Apr 2017
Currently there are no approved pharmacological treatments for non-alcoholic fatty liver disease (NAFLD), including the subtype non-alcoholic steatohepatitis (NASH).
Topic Clinical trials
Trialtrove
01 Apr 2017
Data for this informative report comes from Trialtrove, Pharmaprojects, and Datamonitor Healthcare, all part of the Citeline suite of tools from Pharma Intelligence.
Topic Research
Sitetrove
By Loni Branon 24 Mar 2017
Enrollment success...This is what we all strive for but unfortunately it does not always happen and there is no money-back guarantee.
Topic Clinical trials
Sitetrove
By Loni Branon 24 Mar 2017
Enrollment success...This is what we all strive for but unfortunately it does not always happen and there is no money-back guarantee.
Topic Clinical trials
Pharmaprojects, Biomedtracker, Trialtrove
By Rachel Meighan-Mantha 22 Mar 2017
Epigenetic Drugs in Oncology: Current Clinical Landscape and Emerging Trends
Pharmaprojects
22 Mar 2017
With the recent controversy surrounding the approval and launch of the first wave of PCSK9 inhibitors (focussing mainly on the extremely high cost in comparison to statin therapies), it may be easy to forget that the dyslipidaemia space has also been plagued by a number of high profile and costly failures too.
No Records Found
Request a live demo
Getting a demo tailored to your needs is the best way to see how our solutions will help you gain an advantage.
Request live demo now:
How can we help you?
Our team is always happy to hear from you. Please call us at:
Report store
Have an immediate and specific information need?
Browse and buy from 1000s of analysis and research reports now:
